An update from Amylyx adapted from two Biopharma Dive articles:
Approximately 3,800 PALS were taking Relyvrio at the end of June, Amylyx said in a conference call held Thursday to discuss the company’s second quarter earnings. That’s a step up from the estimated 3,000 patients who were on...